Genocea Biosciences Inc. (GNCA) Given Average Rating of “Buy” by Analysts
Genocea Biosciences Inc. (NASDAQ:GNCA) has received a consensus recommendation of “Buy” from the five ratings firms that are currently covering the firm. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $14.25.
A number of brokerages have recently commented on GNCA. Zacks Investment Research cut shares of Genocea Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday, July 6th. FBR & Co reissued a “buy” rating on shares of Genocea Biosciences in a research note on Monday, August 8th. Piper Jaffray Cos. dropped their price target on shares of Genocea Biosciences from $9.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, September 29th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Genocea Biosciences in a research note on Thursday, September 29th.
A number of large investors have recently made changes to their positions in the company. Franklin Resources Inc. boosted its stake in shares of Genocea Biosciences by 37.0% in the first quarter. Franklin Resources Inc. now owns 2,886,600 shares of the company’s stock valued at $22,342,000 after buying an additional 779,400 shares during the period. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Genocea Biosciences during the first quarter valued at about $662,000. Paloma Partners Management Co acquired a new stake in shares of Genocea Biosciences during the second quarter valued at about $334,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Genocea Biosciences during the first quarter valued at about $565,000. Finally, Vanguard Group Inc. boosted its stake in shares of Genocea Biosciences by 9.5% in the second quarter. Vanguard Group Inc. now owns 656,515 shares of the company’s stock valued at $2,691,000 after buying an additional 57,062 shares during the period. 56.50% of the stock is currently owned by institutional investors.
Genocea Biosciences (NASDAQ:GNCA) remained flat at $4.11 during trading on Tuesday. The company had a trading volume of 78,492 shares. Genocea Biosciences has a 12 month low of $2.56 and a 12 month high of $8.07. The company’s market cap is $116.45 million. The firm has a 50-day moving average price of $5.06 and a 200-day moving average price of $4.70.
Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.05. Genocea Biosciences had a negative net margin of 5,121.17% and a negative return on equity of 47.87%. Equities research analysts anticipate that Genocea Biosciences will post ($1.63) earnings per share for the current year.
About Genocea Biosciences
Genocea Biosciences, Inc is a biopharmaceutical company. The Company discovers and develops vaccines and immunotherapies. It uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company operates through business of developing and commercializing vaccines segment.
Receive News & Stock Ratings for Genocea Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences Inc. and related stocks with our FREE daily email newsletter.